Tegaserod
Top View
- Therapeutic Drug Guidelines for ATCS
- Drugs/Medications Known to Cause Hyperhidrosis Certain Prescriptions
- Theoretical Study of the Interaction of Agonists with the 5-HT2A Receptor
- Australian Adverse Drug Reactions Bulletin, Feb 2003
- Meta-Analysis: the Treatment of Irritable Bowel Syndrome
- Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission R ICHARD A
- Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission
- Emerging Drug List TEGASEROD
- 5-HT Receptor Agonists in the Treatment of Gastrointestinal Motility Disorders
- New Pharmaceutical Approaches to the Treatment of IBS: Future Development & Research
- Nonclinical Cardiovascular Studies of Prucalopride, a Highly Selective 5-Hydroxytryptamine 4 Receptor Agonist S
- Tegaserod Inhibits Noxious Rectal Distention Induced Responses and Limbic System C-Fos Expression in Rats with Visceral Hypersensitivity
- PROGRAM NEWS SUPPORT Act Requirements FALL 2019 Implemented October 1, 2019
- FDA Introductory Remarks Gastrointestinal Drugs Advisory Committee
- WO 2009/092994 Al
- (12) Patent Application Publication (10) Pub. No.: US 2014/0166027 A1 FUSZ Et Al
- Irritable Bowel Syndrome (IBS): Introduction
- Therapeutic Drug Class